Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine

Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy

(2018) Francesca Carozzi et al.   BMC INFECTIOUS DISEASES

Substantial decline in prevalence of vaccine-type and non-vaccine type HPV in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway

(2018) Berit Feiring et al.   JOURNAL OF INFECTIOUS DISEASES

Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination

(2018) Dorothy A Machalek et al.   JOURNAL OF INFECTIOUS DISEASES

Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data

(2018) Simopekka Vänskä et al.   VACCINE

Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden

(2018) Eva Herweijer et al.   VACCINE

Explanations for the high potency of HPV prophylactic vaccines

(2018) John Schiller et al.   VACCINE

Status of HPV vaccine introduction and barriers to country uptake

(2018) K.E. Gallagher et al.   VACCINE

Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions

(2018) Christian Dehlendorff et al.   VACCINE

Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up

(2018) Lihui Wei et al.   VACCINE

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

(2018) Cyra Patel et al.   Eurosurveillance

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

(2017) Kimberley Kavanagh et al.   LANCET INFECTIOUS DISEASES

Non-Vaccine-Type HPV Prevalence after Vaccine Introduction

(2017) Mónica Saccucci et al.   SEXUALLY TRANSMITTED DISEASES

Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction

(2017) Lili Ding et al.   VACCINE

Human Papillomavirus (HPV) Detection in Cytologic Specimens

(2017) Michel P. Bihl et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

(2016) Rengaswamy Sankaranarayanan et al.   LANCET ONCOLOGY

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

(2015) Mélanie Drolet et al.   LANCET INFECTIOUS DISEASES

Human papillomavirus DNA and p16INK4a expression in hypopharyngeal cancer and in relation to clinical outcome, in Stockholm, Sweden

(2015) Tina Dalianis et al.   ORAL ONCOLOGY

Follow-up on oral and cervical human papillomavirus prevalence 2013–2015 in youth at a youth clinic in Stockholm, Sweden

(2015) Nathalie Grün et al.   Infectious Diseases

Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer

(2014) Cecilia Nordfors et al.   ORAL ONCOLOGY

Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination

(2013) J. E. Tota et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

HPV and HPV-Associated Diseases

(2013) Eileen F. Dunne et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

The human papillomavirus family and its role in carcinogenesis

(2013) Massimo Tommasino   SEMINARS IN CANCER BIOLOGY

Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992–2009

(2012) Tonia Forte et al.   CANCER CAUSES & CONTROL

Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer

(2012) Gordana Halec et al.   INTERNATIONAL JOURNAL OF CANCER

Prevalence of Human Papillomavirus (HPV) types in cervical cancer 2003–2008 in Stockholm, Sweden, before public HPV vaccination

(2011) Juan Du et al.   ACTA ONCOLOGICA

Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15–23-year-old women attending a youth health clinic in Stockholm, Sweden

(2010) Torbjörn Ramqvist et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES